Adverum Biotechnologies (ADVM)
(Real Time Quote from BATS)
$7.17 USD
+0.14 (1.99%)
Updated Sep 12, 2024 01:26 PM ET
2-Buy of 5 2
F Value C Growth D Momentum D VGM
Price, Consensus and EPS Surprise
ADVM 7.17 +0.14(1.99%)
Will ADVM be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ADVM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ADVM
Wall Street Analysts See a 332.28% Upside in Adverum Biotechnologies (ADVM): Can the Stock Really Move This High?
Ginkgo (DNA) to Report Q2 Earnings: What's in the Cards?
ADVM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is a Beat in the Cards for Incyte (INCY) in Q2 Earnings?
What's in Store for Structure Therapeutics (GPCR) in Q2 Earnings?
Geron (GERN) to Report Q2 Earnings: What's in the Cards?
Other News for ADVM
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Adverum Biotechnologies reports inducement grants under Nasdaq listing rule
Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences
Adverum Biotechnologies price target lowered by $20 at Truist, here's why
Adverum Biotechnologies price target lowered by $3 at RBC Capital, here's why